Biolidics Limited (SGX: 8YY)

Singapore flag Singapore · Delayed Price · Currency is SGD
0.0100
0.00 (0.00%)
At close: Nov 13, 2024
-37.50%
Market Cap 16.91M
Revenue (ttm) 1.28M
Net Income (ttm) -2.81M
Shares Out 1.69B
EPS (ttm) -0.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,427,400
Open 0.0100
Previous Close 0.0100
Day's Range 0.0100 - 0.0110
52-Week Range 0.0080 - 0.0180
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date Nov 13, 2024

About Biolidics

Biolidics Limited, a precision medicine medical technology company, focuses on developing a portfolio of diagnostic solutions. The company operates through Cancer, Infectious Diseases, and Laboratory Services segments. It provides Covid-19 PCR testing kits. The company offers ClearCell FX1 System, an automated device that separates and enriches cancer cells from blood; and antigen and antibody test kits, as well as laboratory services. It serves academic and research institutes, hospitals, and laboratories in Singapore, China, Hong Kong, Japan,... [Read more]

Industry Electromedical and Electrotherapeutic Apparatus
Founded 2009
Employees 15
Stock Exchange Singapore Exchange - Catalist
Ticker Symbol 8YY
Full Company Profile

Financial Performance

In 2023, Biolidics's revenue was 1.36 million, a decrease of -48.85% compared to the previous year's 2.66 million. Losses were -2.49 million, -73.46% less than in 2022.

Financial Statements

News

There is no news available yet.